Document Detail


Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
MedLine Citation:
PMID:  21749885     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiotoxicity remains the limiting factor for many forms of cancer therapy and is the focus of growing research and clinical emphasis. This article outlines the current clinical evidence for left ventricular dysfunction and heart failure for the two most important classes of cardiotoxic chemotherapeutic agents, examines the potential pitfalls that have led to underestimated rates of left ventricular dysfunction from these agents, and reviews strategies for screening for and providing prophylaxis against chemotherapy-associated left ventricular dysfunction.
Authors:
Ronald M Witteles; Michael B Fowler; Melinda L Telli
Related Documents :
19577075 - Chronic septal infarction confers right ventricular protection during mechanical left v...
11165965 - Normal development of the pulmonary veins in human embryos and formulation of a morphog...
16416475 - The impact of interventional cardiology for the management of adults with congenital he...
633015 - Intestinal function in infants with severe congenital heart disease.
2960725 - Right ventricular hypertrophy is an important determinant of right ventricular infarcti...
24620215 - Two biomarkers for the screening of cardiac risk among runners?
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-14
Journal Detail:
Title:  Heart failure clinics     Volume:  7     ISSN:  1551-7136     ISO Abbreviation:  Heart Fail Clin     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-13     Completed Date:  2011-12-13     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  101231934     Medline TA:  Heart Fail Clin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  333-44     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Affiliation:
Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Falk CVRC, Stanford, CA 94305, USA. witteles@stanford.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects*
Antineoplastic Agents / administration & dosage,  adverse effects
Biomarkers, Pharmacological*
Cardiac Imaging Techniques / methods*
Cardiotoxins
Clinical Trials as Topic
Drug Monitoring / methods*
Humans
Neoplasms / drug therapy
Outcome and Process Assessment (Health Care)
Protein Kinase Inhibitors / administration & dosage,  adverse effects
Quinazolines / administration & dosage,  adverse effects*
Severity of Illness Index
Ventricular Dysfunction, Left* / chemically induced,  diagnosis,  epidemiology,  prevention & control
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/Biomarkers, Pharmacological; 0/Cardiotoxins; 0/Protein Kinase Inhibitors; 0/Quinazolines; 0VUA21238F/lapatinib; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherap...
Next Document:  Stem Cell Therapy for Cardiac Disease: What Can Be Learned from Oncology.